###begin article-title 0
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 37 59 37 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 37 58 <span type="species:ncbi:1496">Clostridium difficile</span>
Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 280 301 280 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 69 90 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 280 301 <span type="species:ncbi:1496">Clostridium difficile</span>
The increased severity of disease associated with the NAP1 strain of Clostridium difficile has been attributed to mutations to the tcdC gene which codes for a negative regulator of toxin production. To assess the role of hyper-production of Toxins A and B in clinical isolates of Clostridium difficile, two NAP1-related and five NAP1 non-related strains were compared.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
Sequencing was performed on tcdC, tcdR, and tcdE to determine if there were differences that might account for hyper-production of Toxin A and Toxin B in NAP1-related strains. Biological activity of Toxin B was evaluated using the HFF cell CPE assay and Toxin A biological activity was assessed using the Caco-2 Trans-membrane resistance assay.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
Our results confirm that Toxin A and Toxin B production in NAP1-related strains and ATCC 43255 occurs earlier in the exponential growth phase compared to most NAP1-nonrelated clinical isolates. Despite the hyper-production observed in ATCC 43255 it had no mutations in tcdC, tcdR or tcdE. Analysis of the other clinical isolates indicated that the kinetics and ultimate final concentration of Toxin A and B did not correlate with the presence or lack of alterations in tcdC, tcdR or tcdE.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
Our data do not support a direct role for alterations in the tcdC gene as a predictor of hyperproduction of Toxin A and B in NAP1-related strains.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 10 32 10 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 39 51 39 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 10 31 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 39 51 <span type="species:ncbi:1496">C. difficile</span>
Toxigenic Clostridium difficile causes C. difficile-associated diarrhea (CDAD) which is a predominant nosocomial infection in Canada as well as other countries [1-15]. In Manitoba, in 2008, there were 890 lab-confirmed cases of CDAD versus 535 total cases of infectious diarrhea due to all other bacterial enteric pathogens combined [16].
###end p 11
###begin p 12
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 393 406 393 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 828 831 828 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdt</italic>
###xml 857 858 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 947 950 947 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcd</italic>
###xml 1055 1068 1055 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 1069 1070 1069 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1071 1072 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1254 1255 1254 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1513 1514 1513 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 393 405 <span type="species:ncbi:1496">C. difficile</span>
###xml 1055 1067 <span type="species:ncbi:1496">C. difficile</span>
Recently published data indicates that although CDAD incidence varies by geographic region there is evidence that overall it is increasing [2,4,5,7,12-15,17]. In Quebec there were 35.6 cases per 100,000 population in 1991 versus 156.3 cases per 100,000 in 2003 [2]. The severity of infection as assessed by mortality rates has increased in certain geographic locations [2-4,7,8,15,18,19]. The C. difficile strain designated NAP1 (equivalent to PCR ribotype 027) was the most prevalent strain associated with the Quebec outbreak of CDAD [4,5,7,8,15] and it has been found in other parts of Canada as well [20]. The significant increase in incidence and disease severity reported for the Quebec outbreak have prompted investigations to determine if this strain has some unique virulence characteristics. This strain has the gene (cdtB) encoding binary toxin [4,18,21,22] and this has been suggested to contribute to disease severity [15,23,24]. The tcdC gene is the putative negative regulator for toxin production within the pathogenicity locus (PaLoc) of C. difficile [3,4,15,20,25] and deletions in this gene have been suggested to affect the regulatory function and account for the apparent high levels of toxin production of the NAP1 outbreak strain [4,20,25]. The initial studies used in vitro ELISA to quantify the production of Toxin A and B relative to the growth curve for the a collection of NAP1 strains that were toxinotype III compared to the a collection of clinical isolates that were toxinotype 0 [4]. Because there may be differences in the biological activity versus antigen detected, further data evaluating the biological levels of Toxins A and B are needed.
###end p 12
###begin p 13
###xml 175 187 175 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE </italic>
###xml 175 187 <span type="species:ncbi:1496">C. difficile</span>
The objective of this study was to provide correlation between the kinetics of toxin production using functional assays and the growth kinetics of various clinical strains of C. difficile. The primary focus of this study was to evaluate the effects of the tcdC region deletions that have been described (18 bp and 1 bp deletions) on the kinetics of biologically active Toxin A and B production. This was done in the context of clinical isolates, thereby evaluating the role of this gene in the overall kinetics of toxin A and B production. Genetic analysis of the tcdR and tcdE regions was also performed to determine if deletions or mutations in these genes accounted for differences in toxin A and B production.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Bacterial strains
###end title 15
###begin p 16
###xml 17 30 17 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 17 29 <span type="species:ncbi:1496">C. difficile</span>
Eight strains of C. difficile were selected for analysis of the growth dynamics and toxin production. Three historical clinical isolates (strains1083, 81A330, and 79A292) were obtained from the culture collection at the National Microbiology Laboratory (NML). Two NAP1-related clinical isolates (strains 57A, 83) were provided by Dr. Paul Levett at the Saskatchewan Provincial Health Laboratory. Strains from the American Type Culture Collection included; ATCC 43255, ATCC 43594 (both are toxigenic strains) and ATCC 700057 (non-toxigenic strain).
###end p 16
###begin title 17
Polymerase chain reaction and sequencing
###end title 17
###begin p 18
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 237 238 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
PCR was carried out with AmpliTaq Gold in PCR Buffer II (Applied Biosystems) with 0.2 mM dNTPs, 3 mM MgCl2, and various primer concentrations, at an annealing temperature of 58degreesC. The primers used in this study are listed in Table 1.
###end p 18
###begin p 19
Primers used in this evaluation.
###end p 19
###begin p 20
###xml 26 39 26 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 148 161 148 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 26 38 <span type="species:ncbi:1496">C. difficile</span>
###xml 148 160 <span type="species:ncbi:1496">C. difficile</span>
Strains were confirmed as C. difficile and putative toxigenic status determined by two PCR multiplexes, [26] one consisting of the tpi-F/R primers (C. difficile triose phosphate isomerase housekeeping gene) and the tcdA-F/R primers (toxin A), and one consisting of the PaL15/16 primers (tcdC), cdtB-pos/rev primers (binary toxin subunit B), and tcdB-3/4 primers (toxin B).
###end p 20
###begin p 21
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
Genes and flanking regions were amplified for sequence analysis (Table 2) with primers TPR-1/tcdB-UP (tcdR), Lok6/PrimexA (tcdE), and cdd1-A/tcdC3 (tcdC). Oligonucleotides were synthesized, and dideoxy cycle sequencing carried out by the Genomics Core Facility of the NML.
###end p 21
###begin p 22
GeneBank Accession numbers for genes sequenced.
###end p 22
###begin p 23
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a </italic></sup>
a n.d., not deposited as the sequence for this region was 100% identical to the same region from strain 57A.
###end p 23
###begin p 24
* The 1 bp deletion is at position 272 of the  gene sequence. The deletion causes a frameshift resulting in an in-frame stop codon at position 275-277 of the  sequence.
###end p 24
###begin p 25
** The 1 bp substitution that results in a transversion of C to A is at position 695 of the DQ272240 sequence.
###end p 25
###begin p 26
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Selective regions of the Toxin A and B were analyzed following [27] toxinotyping procedure using the B1C and B2N primers to amplify region B1 and A3C and A4N primers to amplify region A3.
###end p 26
###begin p 27
###xml 42 44 42 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Binary toxin PCR was performed following [28] procedure using the cdtB primers cdtBpos and cdtBrev.
###end p 27
###begin title 28
Growth conditions
###end title 28
###begin p 29
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 490 492 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 0 12 <span type="species:ncbi:1496">C. difficile</span>
###xml 66 71 <span type="species:ncbi:9940">sheep</span>
C. difficile strains were grown on Tryptic soy agar containing 5% sheep blood (BA) (Oxoid Nepean, ON) that were incubated at 37degreesC in a Bactron anaerobic chamber (Sheldon Manufacturing Cornelius, OR). Prior to each experiment, 48 hour pure cultures on BA were subcultured into pre-reduced Brain Heart Infusion broth (BHI) (Difco Kanasas City, MO). After overnight growth at 37degreesC each culture was used to inoculate BHI (10 mls) or to provide a final bacterial concentration of ~103 cfu/ml. The inoculated BHI culture in Hungate tubes (screw cap with a rubber septum facilitated aspiration of samples) was incubated at 37degreesC and samples were taken at various time frames over 60 hours to determine viable count and toxin A and B titres using the methods described below.
###end p 29
###begin title 30
Bacterial Quantitation
###end title 30
###begin p 31
###xml 95 117 95 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 95 116 <span type="species:ncbi:1496">Clostridium difficile</span>
Samples were serially diluted 1:10 in BHI and then 0.1 ml of each dilution was inoculated onto Clostridium difficile Moxalactam Norfloxacin (CDMN) agar plates (Oxoid Nepean, ON) using the spread plate technique. All counts were performed in triplicate after 48 hours incubation and the average +/- standard deviation was determined.
###end p 31
###begin p 32
Spores were detected using alcohol shock and quantitative count using the CDMN spread plate technique.
###end p 32
###begin title 33
Cell Culture
###end title 33
###begin p 34
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human foreskin fibroblast (HFF) cells, were used for the Toxin B cytotoxin assay as described by Du et al. [30]. Cells were examined for cytopathic effect (CPE) at 48 hours and a monolayer with at least 50% cell rounding was considered positive for CPE [29]. The titer was reported as the reciprocal of the highest dilution positive for CPE. All results for Toxin B titres were reported as mean +/- standard deviation from triplicate experiments. Purified Toxin B (Techlab Blackburg, VA), and myeloma media were included as positive and negative controls respectively. Bartel's (Carlsbad, CA) Toxin B control was also used as a positive control.
###end p 34
###begin p 35
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 387 389 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 390 392 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The Caco-2 cells (ATCC HTB 37), were maintained and used for the Toxin A tight-junction assay, in Transwell inserts (Corning Costar Corning, NY) as described by Du et al. [30] as modification of Grasset et al. [31] method. The transepithelial resistance (TER) was measured using Millicell-ERS (Millipore) and the monolayer was considered to be confluent when the TER was >/= 400 Omega/cm2 [30]. Samples were considered positive for Toxin A if a 50% drop in resistance was seen within 360 minutes of inoculating the insert. Purified Toxin A, Lot 0195005 (Techlab Blackburg, VA) at 460 ng/ml and cell culture media alone were included as positive and negative controls respectively.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 88 101 88 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 88 100 <span type="species:ncbi:1496">C. difficile</span>
The objective of this study was to evaluate a variety (Figure 1) of clinical strains of C. difficile (NAP1 related and NAP1 non-related) to determine if there was a correlation between the genetic changes detected in the putative negative regulator gene (tcdC) and the growth kinetics and toxin production. The relatedness of strains was assessed by pulsed-field gel electrophoresis (Figure 1) using SmaI as the restriction enzyme following the method of [32].
###end p 37
###begin p 38
###xml 19 41 19 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characteristics of <italic>Clostridium difficile </italic>strains</bold>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdA </italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdB </italic>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 19 40 <span type="species:ncbi:1496">Clostridium difficile</span>
Characteristics of Clostridium difficile strains. All strains had tcdA and tcdB as the appropriate size of A3 and B1 amplicon was detected.[27] To assess NAP1 relatedness, PFGE analysis was performed using Sma1 as outlined by[32].
###end p 38
###begin p 39
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The seven strains were assessed to confirm that both Toxin A and B genes were present and to ensure that there were not any large deletions within the B1 or A3 regions [27,33] of the pathogenicity locus (PaLoc). In addition sequencing was used to evaluate any changes in the positive regulator gene tcdR, the putative toxin secretory gene tcdE, as well as the putative negative regulator gene tcdC. The results of these analyses are shown in Figure 1.
###end p 39
###begin p 40
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 209 211 207 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 518 520 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2G</xref>
The results of the growth kinetic studies are shown in Figure 2. A clear segregation of strains was observed, as such strains were considered to be high-level producers (HLP) if the titre of Toxin B was >/= 103 CPE units per ml by 48 hours incubation. The ATCC 43255 strain and the NAP1-related clinical isolates all produced high titres of biologically active Toxin B in broth culture whereas ATCC 43594 and the other three clinical isolates did not. The clinical strain 1083 was the slowest Toxin B producer (Figure 2G) and this was confirmed using multiple repeated growth curves (data not shown).
###end p 40
###begin p 41
###xml 52 64 52 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Toxin B production over time for various strains of <italic>C. difficile</italic></bold>
###xml 52 64 <span type="species:ncbi:1496">C. difficile</span>
Toxin B production over time for various strains of C. difficile. The viable count (line) and Toxin B production (black bars) were determined over 60 hours for isolates grown in BHI broth. The strains evaluated included; ATCC 43255 (A), ATCC 43594 (B), NAP1 clinical strain 57A (C), NAP1 clinical strain 83 (D), historical clinical strains 79A292 (E), 81A330 (F) and 1083 (G).
###end p 41
###begin p 42
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
To determine if these strains had differing levels of biologically active Toxin A production, samples from cultures of each strain under the same growth conditions were evaluated at 24 and 48 hours post-inoculation. The ATCC 43255 strain produced more biologically active Toxin A than any of the other strains when 24 hour cultures were evaluated. By 48 hours (Figure 3), both NAP-related strains (83 and 57A) had reduced the trans-membrane resistance to < 30% whereas this TER was not seen for NAP1-unrelated strains.
###end p 42
###begin p 43
###xml 20 33 20 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Toxin A activity of <italic>C. difficile </italic>strains grown in BHI broth culture</bold>
###xml 20 32 <span type="species:ncbi:1496">C. difficile</span>
Toxin A activity of C. difficile strains grown in BHI broth culture. The Toxin A activity for 48 hour culture supernatants was determined using the trans-membrane resistance assay. The positive control consisted of purified Toxin A (460 ng/ml) and the negative control was BHI broth. Strain 700057 is a strain that in a non-toxin producing strain.
###end p 43
###begin p 44
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 193 196 193 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 283 285 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 290 292 290 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 394 396 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
Alcohol shock was used to determine what portion of the total viable count was in the spore form (Figure 4). The only major difference in spore formation noted was that strain 43255 had < 1 Log10 of spores after 24 hours incubation whereas all the other strains tested had between 102 to 105 spores/ml. By 48 and 72 hours incubation all strains had ~105 spores/ml from a total population of ~107 cfu/ml (i.e. viable count is predominantly in the vegetative form).
###end p 44
###begin p 45
###xml 24 37 24 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sporulation activity of <italic>C. difficile </italic>strains grown in BHI broth culture</bold>
###xml 104 117 104 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 199 212 199 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 574 576 569 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 24 36 <span type="species:ncbi:1496">C. difficile</span>
###xml 104 116 <span type="species:ncbi:1496">C. difficile</span>
###xml 199 211 <span type="species:ncbi:1496">C. difficile</span>
Sporulation activity of C. difficile strains grown in BHI broth culture. Spore production by strains of C. difficile grown in BHI broth for 24 (A), 48 (B) and 72 hours (C). The total viable count of C. difficile (square) was determined as well as an assessment using alcohol shock (as described in the Materials and Methods) to determine what portion was in the spore form (â– ). Each bar represents the average of triplicate testing. The 24 hour levels for strain 43255 were tested in triplicate on two separate occasions to verify that spore levels were consistently < 1 Log10.
###end p 45
###begin p 46
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 672 675 672 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcd</italic>
The promoter region of tcdC (-35 to -10 bp upstream of the tcdC gene as described by Hunsdsburger et al. [34]) was sequenced to determine if the strains evaluated had any differences. An alignment of the sequences showed that all strains had identical promoter sequences (data not shown). Sequencing of the tcdC gene itself demonstrated that there were deletions that would lead to a premature termination codon in the protein sequence that would affect the expected length of the protein product (Figure 1). Alignment of the amino acid sequences is shown in Figure 5. It is apparent that for strains 1083, 57A and 83 that the proteins transcribed and translated from the tcdC gene would be substantially shorter compared to the other strains evaluated that had no deletions or premature stop codons. Although the truncated proteins are somewhat similar in length (63 vs 65 amino acids long), the position of the 1 bp change leads to very different amino acid sequence changes. Strain 1083 has a 1 bp substitution at position 191 that results in a C to A transversion that creates a premature stop codon and results in a 63 amino acid long protein that has an unchanged amino acid sequence up to position 174. Whereas the 1 bp deletion at position 117 in strains 57A and 83 results in a frame shift that leads to an altered amino acid sequence from position 117 onwards and a premature stop codon at positions 187-189 resulting in a predicted product of 65 amino acids.
###end p 46
###begin p 47
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 67 79 67 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amino acid sequence alignment from <italic>tcdC </italic>gene of various strains of <italic>C. difficile</italic></bold>
###xml 67 79 <span type="species:ncbi:1496">C. difficile</span>
Amino acid sequence alignment from tcdC gene of various strains of C. difficile. Amino acids identical to the ATCC 43225 sequence (shown) are indicated by periods, differences are shown, and the region of the six amino acid deletions (dashes) in strains 79A292 and 81A330 are boxed. The transmembrane helical regions (TMH) are indicated by a line.
###end p 47
###begin p 48
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE </italic>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The sequence analysis of the tcdR genes of the seven strains were identical (data not shown). Sequence analysis of tcdE revealed that only strain 1083 had any deletions. This 1 bp deletion in strain 1083 causes a frame-shift and leads to a stop codon after 18 amino acids compared to expected protein product of 166 amino acids for all other strains (Figure 1).
###end p 48
###begin p 49
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdtB </italic>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Because cdtB was detected by PCR, binary toxin was presumed to be produced by the NAP1-related strains 57A and 83 as well as 81A330 and 1083 which are NAP1-unrelated strains by PFGE (Figure 1).
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
Our results demonstrated that deletions in the tcdC gene cannot be used to predict hyperproduction of Toxin A or B in clinical isolates. Assessment of deletions in this gene could be very misleading if used as a diagnostic approach in patients with CDAD to try to predict who will have more severe disease. Furthermore, our data suggested that tcdC deletions may not be the sole factor responsible for the increased toxin production observed in the NAP-1 isolates. Studies of toxin production using isogenic mutants are warranted to confirm our results.
###end p 51
###begin p 52
###xml 113 126 113 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 329 334 329 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR </italic>
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 762 767 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 789 802 789 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 1043 1048 1043 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 1112 1121 1112 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1615 1620 1615 1620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 113 125 <span type="species:ncbi:1496">C. difficile</span>
###xml 789 801 <span type="species:ncbi:1496">C. difficile</span>
There are a number of possible explanations for what has been referred to as "hyperproduction" of toxins by some C. difficile strains and not by others. If the positive regulator tcdR was genetically altered in various strains it might result in differing toxin expression between strains. Our sequencing data indicates that the tcdR gene in all strains is identical ruling out genetic differences in the positive regulator gene as an explanation of differences in Toxin A and B production. An alternative mechanism for "hyperproduction" might be that the putative negative regulator tcdC is mutated thereby allowing earlier and more efficient expression of toxin due to the lack of a functional negative regulator. Although there were multiple changes found in tcdC in various strains of C. difficile (e.g. 57A, 83, and 1083) that resulted in predicted truncated proteins that are likely not active, these defects do not always correlate with increased toxin expression. Furthermore, strain ATCC 43255 does not have deletions or mutations in tcdC yet it has the highest levels of Toxin B and Toxin A production in vitro (higher even than the NAP1-related clinical isolates). Strains can differ in the proportion of the population that is in the spore form and this might explain the differences in secreted toxin levels. However, the growth conditions in our study did not result in variation in spore levels for the different strains evaluated. Therefore, the differences in toxin production observed cannot be explained by differences in spore form population. Our data therefore suggest that alterations in the tcdC gene sequence are not accurate predictors of hyper-production of Toxin B or Toxin A.
###end p 52
###begin p 53
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
The ATCC 43255 strain is a known hyperproducer of Toxin B [6,10,36] and our data for biologically active toxin production in BHI broth culture support this determination. The use of ATCC 43255 as the "type strain" may be misleading as Warny et al. [4] assessed 25 Toxinotype 0 clinical isolates (non NAP1-related) and reported that hyperproduction of toxin is not common in non-NAP1 clinical isolates.
###end p 53
###begin p 54
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
The TcdC protein has a predicted transmembrane domain [34] which was lost for the truncated product and altered amino acid sequence for strains 57A and 83. However, the transmembrane folding motif for TcdC was retained for strain 1083 despite the truncation of this protein. Despite this retained transmembrane motif for strain 1083 it is unlikely that the TcdC protein is fully functional when only a predicted 63 of the total 232 amino acids are present.
###end p 54
###begin p 55
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE </italic>
###xml 663 668 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 1013 1017 1013 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
###xml 1106 1111 1106 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE </italic>
Another possible explanation for increased toxin activity in our experiments might be that secretion of the toxins outside the bacterial cell is increased in "hyperproducing" strains. Sequencing of tcdE indicates that there are no differences in this gene in the strains evaluated except for strain 1083 that has a 1 bp deletion that results in a truncated product of 18 amino acids compared to the expected size of 166 amino acids. If secretion was negatively impacted because the TcdE protein product was non-functional (i.e. unable to secrete toxins properly), this might explain why the levels of Toxin B were low in this strain despite the truncation to the tcdC gene that is suspected to predict toxin hyperproduction. Our study evaluated the levels of secreted toxin B, therefore, the levels of toxin detected in our assays would be low if the strain had decreased ability to secrete toxin. However, there are other strains (e.g. 79A292 and 81A330) that are low toxin producers that do not have defects in tcdE. Furthermore, neither ATCC 43255 nor the NAP1-related clinical isolates have defects in tcdE yet they produce high titres of biologically active Toxin B in broth culture.
###end p 55
###begin p 56
###xml 36 37 36 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 941 954 941 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 1112 1116 1112 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdE</italic>
###xml 1118 1123 1118 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 1126 1130 1126 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 1193 1194 1193 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1195 1197 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1227 1232 1227 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 941 953 <span type="species:ncbi:1496">C. difficile</span>
Our data confirms previous reports [4,37] as near maximal biologically active Toxin B production was reached earlier in the growth curve (24 hours) of "hyperproducing" strains in BHI compared to "non-hyperproducing" strains (36 to 48 hours). We found that "hyperproducing" strains produced 100 to 1000 fold more Toxin B at 24 and 48 hours in BHI compared to "non-hyperproducing" strains. Our studies focused on biological activity of Toxin A and B whereas, Warny et al. [4] assessed total protein concentration irrespective of functionality, so this may explain the difference in ratios between "hyperproducing" and "non-hyperproducing" strains. Both studies assessed the culture supernatant from broth cultures as the source of secreted toxin. We used BHI broth and Warny et al. [4] used an Acambis proprietary broth media, so there may be some differences in the kinetics of toxin production due to different growth medium. In our studies C. difficile strain 43255 produced the highest levels of biologically active Toxin B in BHI broth culture compared to all other strains tested, yet it has no deletions in tcdE, tcdC or tcdR, therefore, our data do not support the conclusion by others [4,35] that the mutations found in tcdC of NAP1 strains accounts for their higher Toxin B production.
###end p 56
###begin p 57
###xml 39 41 39 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 811 824 811 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 891 894 891 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcd</italic>
###xml 924 928 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdR</italic>
###xml 944 957 944 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 1107 1109 1107 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 1275 1277 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 811 823 <span type="species:ncbi:1496">C. difficile</span>
###xml 944 956 <span type="species:ncbi:1496">C. difficile</span>
The recent study of Matamouros et al. [37] used cloning experiments and concluded that tcdR, which is a positive regulator for Toxin A and B production, was under the negative regulatory control of tcdC. They concluded that the TcdC protein product does not directly interact with the Toxin A promoter but rather interacts with TcdR to prevent it from functioning properly and thereby causing a negative impact on Toxin A production (i.e. it acts as a sigma-factor antagonist). They suggest that their data provide the first proof that tcdC is a negative regulator and furthermore, they suggest that epidemic strains have mutations in tcdC that result in hyper-production of toxin. Despite their elegant data to show how TcdR is negatively impacted by TcdC, their data do not provide an explanation for why the C. difficile ATCC strain 43255 is a hyper-producer of Toxins A and B (it has no tcdC mutations and has an intact tcdR). Furthermore, C. difficile strain 1083 has a predicted truncated TcdC yet it does not hyper-produce Toxin A or B. Whether the use of the glutamate dehydrogenase promoter for tcdC in these studies (rather than the actual tcdC promoter) has any role in the finding is unknown (all other genes cloned were under control of their natural promoter) [37].
###end p 57
###begin p 58
###xml 256 269 256 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1049 1062 1049 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 1435 1447 1435 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 1482 1491 1482 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1561 1568 1561 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1794 1806 1794 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 1853 1855 1853 1855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 256 268 <span type="species:ncbi:1496">C. difficile</span>
###xml 1049 1061 <span type="species:ncbi:1496">C. difficile</span>
###xml 1435 1447 <span type="species:ncbi:1496">C. difficile</span>
###xml 1604 1610 <span type="species:ncbi:9606">humans</span>
###xml 1740 1748 <span type="species:ncbi:9606">patients</span>
###xml 1794 1806 <span type="species:ncbi:1496">C. difficile</span>
###xml 1867 1872 <span type="species:ncbi:9606">human</span>
The assays used in our study to assess biological activity are different so we cannot directly compare the titres of Toxin B to those of Toxin A. Despite this limitation our data does allow comparison of relative production of each toxin across a range of C. difficile strains. Strain 43255 produced significantly higher titres of biologically active Toxin B and Toxin A in broth culture compared to all other strains. Differences in the binding avidity, or kinetics of glucosyltransferase activity of Toxin A and B was not assessed. Previous studies have reported that mutation of tryptophan-101 in Toxin A (a similar effect was also seen for Toxin B) resulted in reduced glucosyltransferease activity [38]. Our results demonstrated that there was approximately 100-1000-fold higher titres of biologically active Toxin B production after 24 and 48 hours in broth culture for "hyper" versus "non-hyper" producing clinical isolates. Our results were obtained from the analysis of a small number of isolates that were chosen to represent sub-types of C. difficile that have been associated with CDAD. The control strains, ATCC 43255, 43594 and 700057, included the wild-type strain, a second toxigenic strain and a non-toxigenic strain respectively. It is not possible from our data or any of the currently published data to conclusively determine what gene(s) (if any) are responsible for "hyperproduction" of toxins in some strains of C. difficile. Furthermore, the significance of in vitro "hyperproduction" of Toxin A and B may or may not reflect what occurs in vivo. There have been no evaluations of humans infected with "hyperproducing" strains to establish that the titre of Toxin A or B/gram of stool is higher compared to levels in patients infected with non-hyper producing strains of C. difficile. However, the recent study by Freeman et al. [39] using the human gut model showed that post-exposure to clindamycin, the level of Toxin B production was similar for NAP1-related strain and a ribotype 001 strain.
###end p 58
###begin p 59
Our data would suggest that the Caco2 transmembrane resistance assay is an insensitive test method for Toxin A as >/= 460 ng/ml was needed to give a detectable trans-membrane electrical resistance drop whereas >/= 150 ng/ml of Toxin B produced detectable CPE in HFF cells. Alternatively Toxin A activity may degrade more rapidly in BHI broth culture compared to Toxin B activity.
###end p 59
###begin title 60
Conclusion
###end title 60
###begin p 61
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 177 190 177 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC</italic>
###xml 177 189 <span type="species:ncbi:1496">C. difficile</span>
In summary, our data do not support the role of mutations in tcdC as the sole basis for NAP1-related strains being hyper-producers of Toxins A and B. The production of isogenic C. difficile mutants has been described by [40] and this approach may be necessary to clarify the role of tcdC.
###end p 61
###begin title 62
Competing interests
###end title 62
###begin p 63
The authors declare that they have no competing interests.
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
All authors read and approved the final manuscript. MA contributed to the conceptual design, data analysis and writing. RM contributed to the conceptual design, data analysis and writing. PL contributed to the data analysis, writing, and experimental testing. DB contributed to the experimental testing (PCR & PFGE) and writing. MM contributed to the data analysis and writing.
###end p 65
###begin title 66
Pre-publication history
###end title 66
###begin p 67
The pre-publication history for this paper can be accessed here:
###end p 67
###begin p 68

###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
The skilled technical assistance of the Microbiology Department.
###end p 70
###begin article-title 71
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 0 21 <span type="species:ncbi:1496">Clostridium difficile</span>
Clostridium difficile - associated diarrhea in adults
###end article-title 71
###begin article-title 72
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 0 21 <span type="species:ncbi:1496">Clostridium difficile</span>
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity
###end article-title 72
###begin article-title 73
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 0 21 <span type="species:ncbi:1496">Clostridium difficile</span>
Clostridium difficile Toxins: Mechanism of action and role I disease
###end article-title 73
###begin article-title 74
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 42 63 <span type="species:ncbi:1496">Clostridium difficile</span>
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
###end article-title 74
###begin article-title 75
###xml 42 63 42 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 42 63 <span type="species:ncbi:1496">Clostridium difficile</span>
An epidemic, toxin gene-variant strain of Clostridium difficile
###end article-title 75
###begin article-title 76
###xml 73 94 73 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 73 94 <span type="species:ncbi:1496">Clostridium difficile</span>
Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates
###end article-title 76
###begin article-title 77
###xml 55 76 55 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 55 76 <span type="species:ncbi:1496">Clostridium difficile</span>
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality
###end article-title 77
###begin article-title 78
###xml 37 58 37 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 37 58 <span type="species:ncbi:1496">Clostridium difficile</span>
Mortality attributable to nosocomial Clostridium difficile-associated disease furing an epidemic caused by a hypervirulent strain in Quebec
###end article-title 78
###begin article-title 79
###xml 58 79 58 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 58 79 <span type="species:ncbi:1496">Clostridium difficile</span>
Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals
###end article-title 79
###begin article-title 80
###xml 53 75 53 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 53 74 <span type="species:ncbi:1496">Clostridium difficile</span>
Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864 - implications for transcription, expression and enzymatic activity of toxins A and B
###end article-title 80
###begin article-title 81
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 0 21 <span type="species:ncbi:1496">Clostridium difficile</span>
Clostridium difficile - associated diarrhea and colitis
###end article-title 81
###begin article-title 82
###xml 24 46 24 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 24 45 <span type="species:ncbi:1496">Clostridium difficile</span>
Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods
###end article-title 82
###begin article-title 83
###xml 29 51 29 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 29 50 <span type="species:ncbi:1496">Clostridium difficile</span>
Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains
###end article-title 83
###begin article-title 84
###xml 10 32 10 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 10 31 <span type="species:ncbi:1496">Clostridium difficile</span>
Update on Clostridium difficile associated disease
###end article-title 84
###begin article-title 85
###xml 50 72 50 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 138 150 138 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile</italic>
###xml 50 71 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 138 150 <span type="species:ncbi:1496">C. difficile</span>
A portrait of the geographic dissemination of the Clostridium difficile North American Pulsed-Field Type 1 strain and the epidemiology of C. difficile-associated disease in Quebec
###end article-title 85
###begin article-title 86
###xml 7 28 7 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 7 28 <span type="species:ncbi:1496">Clostridium difficile</span>
Severe Clostridium difficile-associated disease in populations previously at low risk - Four States 2005
###end article-title 86
###begin article-title 87
###xml 16 38 16 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 16 37 <span type="species:ncbi:1496">Clostridium difficile</span>
Distribution of Clostridium difficile variant toxintypes and strains with binary toxin genes among clinical isolates in an American hospital
###end article-title 87
###begin article-title 88
###xml 38 60 38 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 38 59 <span type="species:ncbi:1496">Clostridium difficile</span>
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins
###end article-title 88
###begin article-title 89
###xml 22 44 22 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 22 43 <span type="species:ncbi:1496">Clostridium difficile</span>
Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada
###end article-title 89
###begin article-title 90
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 61 83 61 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 61 82 <span type="species:ncbi:1496">Clostridium difficile</span>
Variant Forms of the binary toxin CDT locus and tcdC gene in Clostridium difficile strains
###end article-title 90
###begin article-title 91
###xml 39 61 39 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 39 60 <span type="species:ncbi:1496">Clostridium difficile</span>
ADP-riobsylating binary toxin genes of Clostridium difficile strain CCUG 20309
###end article-title 91
###begin article-title 92
###xml 95 116 95 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 95 116 <span type="species:ncbi:1496">Clostridium difficile</span>
Prevalence and characterization of a binary toxin (Actin-specific ADP-ribosyltransferase) from Clostridium difficile
###end article-title 92
###begin article-title 93
###xml 19 41 19 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 19 40 <span type="species:ncbi:1496">Clostridium difficile</span>
Community-acquired Clostridium difficile diarrhea caused by binary toxin, Toxin A and Toxin B gene-positive isolates in Hungary
###end article-title 93
###begin article-title 94
###xml 131 153 131 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 131 152 <span type="species:ncbi:1496">Clostridium difficile</span>
Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates
###end article-title 94
###begin article-title 95
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tpi </italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdA </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdB </italic>
###xml 124 145 124 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 124 145 <span type="species:ncbi:1496">Clostridium difficile</span>
Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile
###end article-title 95
###begin article-title 96
###xml 24 46 24 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 24 45 <span type="species:ncbi:1496">Clostridium difficile</span>
Revised nomenclature of Clostridium difficile toxins and associated genes
###end article-title 96
###begin article-title 97
###xml 81 102 81 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 81 102 <span type="species:ncbi:1496">Clostridium difficile</span>
Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile
###end article-title 97
###begin article-title 98
###xml 17 38 17 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 81 94 81 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. difficile </italic>
###xml 17 38 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 81 93 <span type="species:ncbi:1496">C. difficile</span>
The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays
###end article-title 98
###begin article-title 99
###xml 17 39 17 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 17 38 <span type="species:ncbi:1496">Clostridium difficile</span>
Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A
###end article-title 99
###begin article-title 100
###xml 25 30 <span type="species:ncbi:9606">human</span>
Epithelial properties of human colonic carcinoma cell line Caco-2: Electrical parameters
###end article-title 100
###begin article-title 101
###xml 66 88 66 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 129 150 129 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 66 87 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 129 150 <span type="species:ncbi:1496">Clostridium difficile</span>
Characterization of a toxin A-negative, toxinB-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea
###end article-title 101
###begin article-title 102
###xml 64 85 64 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 64 85 <span type="species:ncbi:1496">Clostridium difficile</span>
Characterization of polymprphisms in the toxin A and B genes of Clostridium difficile
###end article-title 102
###begin article-title 103
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdA-E </italic>
###xml 73 94 73 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile</italic>
###xml 73 94 <span type="species:ncbi:1496">Clostridium difficile</span>
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile
###end article-title 103
###begin article-title 104
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcdC </italic>
###xml 96 118 96 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile.</italic>
###xml 96 117 <span type="species:ncbi:1496">Clostridium difficile</span>
tcdC Genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile.
###end article-title 104
###begin article-title 105
###xml 14 36 14 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 14 35 <span type="species:ncbi:1496">Clostridium difficile</span>
Expression of Clostridium difficile Toxins A and B and their Sigma Factor TcdD is controlled by temperature
###end article-title 105
###begin article-title 106
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 0 21 <span type="species:ncbi:1496">Clostridium difficile</span>
Clostridium difficile toxin expression is inhibited by the novel regulator TcdC
###end article-title 106
###begin article-title 107
###xml 23 45 23 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 23 44 <span type="species:ncbi:1496">Clostridium difficile</span>
Application of mutated Clostridium difficile Toxin a for determination of glycosyltransferase-dependent effect
###end article-title 107
###begin article-title 108
###xml 67 89 67 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 67 88 <span type="species:ncbi:1496">Clostridium difficile</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 01 and 027 in a human gut model
###end article-title 108
###begin article-title 109
###xml 41 63 41 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Clostridium difficile </italic>
###xml 41 62 <span type="species:ncbi:1496">Clostridium difficile</span>
Construction and analysis of chromosomal Clostridium difficile mutants
###end article-title 109

